LOXL2 and cancer: As AB0023 has previously been reported in preclinical cancer studies to be anti-angiogenic,69 we investigated the functional effect of the antibody on angiogenesis to exclude the possibility that our inability to detect any significant effect of AB0023 on LOXL2 catalytic activity, PYD collagen cross-linking, and tissue stiffness was not due to the loss of antibody efficacy.